Takeda Pharma denied general conditional reimbursement in Denmark

The Danish Medicines Agency has rejected Takeda Pharma’s application for general conditional reimbursement for insomnia treatment Slenyto.

Photo: Hannibal Hanschke/Reuters/Ritzau Scanpix

Takeda Pharma’s insomnia drug Slenyto (melatonin) will not be getting general conditional reimbursement in Denmark, according to a recent decision by the Danish Medicines Agency.

The firm had applied to receive the type of reimbursement classification meaning certain patients who fulfil particular requirements could get their hands on the prescribed drug for cheaper. A general reimbursement without any conditions means that all patients can receive price reductions on the prescribed medicine.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs